<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995627</url>
  </required_header>
  <id_info>
    <org_study_id>NL72495.091.19</org_study_id>
    <nct_id>NCT04995627</nct_id>
  </id_info>
  <brief_title>Salt Supplementation in Gitelman Syndrome</brief_title>
  <official_title>Exploratory Study Into the Effect of Salt Supplementation in Gitelman Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Kidney Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of salt (NaCl) supplementation on serum&#xD;
      potassium and clinical signs and symptoms in patients with Gitelman syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single subject multiple randomized double-blinded multi-crossover placebo-controlled trials&#xD;
      (N-of-1 trials) will be performed. Participants will enroll the study after giving written&#xD;
      informed consent. The individual trials will consist of 3 treatment blocks which each contain&#xD;
      a 4-week treatment period of salt supplementation (12 grams of NaCl) and a 4-week treatment&#xD;
      period of placebo, in a randomized, blinded order. After each period of 4 weeks, outcomes&#xD;
      measures will be measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single subject multiple randomized double-blinded multi-crossover placebo-controlled trials (N-of-1 trials)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum Potassium</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in serum potassium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in symptoms measured by personalized symptom score sheet</measure>
    <time_frame>Weekly (week 0 till week 24)</time_frame>
    <description>Symptoms will be scored via a personalized symptom score sheet, which will be composed with the individual participant. Symptoms will be scored at a range from 0 - 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum sodium</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in serum sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum magnesium</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in serum magnesium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum chloride</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in serum chloride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum bicarbonate</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in serum bicarbonate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum calcium</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in serum calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum creatinine</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum aldosterone</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in serum aldosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum renin</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in serum renin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fractional urinary excretion of potassium</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in fractional urinary excretion of potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fractional urinary excretion of sodium</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in fractional urinary excretion of sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fractional urinary excretion of chloride</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in fractional urinary excretion of chloride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fractional urinary excretion of magnesium</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in fractional urinary excretion of magnesium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary calcium/creatinine ratio</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in urinary calcium/creatinine ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary excretion of renin</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in urinary excretion of renin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary excretion of aldosterone</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Change in urinary excretion of aldosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gitelman symptom questionnaire</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>With the Gitelman symptom questionnaire, symptoms can be scored for frequency of apperance and severity. This questionnaire also contains the 36-Item Short Form Health Survey (RAND SF-36) quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (including orthostatic hypotension measurement)</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Measurement of blood pressure including measurement of orthostatic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Body Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>Baseline, week 4, week 8, week 12, week 16, week 20, week 24</time_frame>
    <description>Muscle strength will be measured by hand grip dynamometer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gitelman Syndrome</condition>
  <arm_group>
    <arm_group_label>Salt (NaCl)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 grams (12 capsules) of NaCl per day&#xD;
Note: participants will be treated with active and placebo comparator (N-of-1 trial design)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>12 capsules of placebo per day&#xD;
Note: participants will be treated with active and placebo comparator (N-of-1 trial design)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Salt (NaCl)</intervention_name>
    <description>12 grams of salt (NaCl) per day</description>
    <arm_group_label>Salt (NaCl)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Genetically-proven, symptomatic Gitelman syndrome&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inability to discontinue potassium-sparing diuretics, mineralocorticoid antagonists&#xD;
             and NSAIDs; this means inability to reach a potassium level of 2.5 mmol/L or higher&#xD;
             with maximally tolerable potassium supplementation after discontinuation of&#xD;
             potassium-sparing diuretics&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Nijenhuis, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maartje FA Verploegen, MD</last_name>
    <phone>+31243614761</phone>
    <email>Maartje.Verploegen@radboudumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maartje FA Verploegen, MD</last_name>
      <phone>+31243614761</phone>
      <email>Maartje.Verploegen@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Tom Nijenhuis, MD PhD</last_name>
      <phone>+31243614761</phone>
      <email>Tom.Nijenhuis@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3000CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewout J Hoorn, MD PhD</last_name>
      <phone>+31107040565</phone>
      <email>e.j.hoorn@erasmusmc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 18, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gitelman Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

